Close Menu

NEW YORK – Magnolia Medical said on Wednesday it has signed a three-year purchasing agreement with Intalere covering Magnolia's Steripath Gen2 Initial Specimen Diversion Device product portfolio.

Other terms of the deal were not disclosed.

As part of the deal, Intalere member hospitals will receive "increased value" and cost savings, as well as access to Magnolia's alliance member pricing and clinical performance guarantee for Steripath. The Steripath Gen2 ISDD product portfolio includes direct-to-media and integrated syringe configurations.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.